

Supporting Information

Transition-metal-free access to 2-aminopyridine derivatives from 2-fluoropyridine and acetamidine hydrochloride

Yibiao Li^{*,a}, Shuo Huang^a, Chunshu Liao^a, Yan Shao^a and Lu Chen^a


Address: School of Biotechnology and Health Sciences, Wuyi University, Jiangmen, Guangdong Province, 529090, China

Email: leeyib268@126.com

I. General methods and materials


Unless otherwise noted, all commercial materials and solvents were used without further purification and all the reactions were carried out in a Schlenk tube equipped with magnetic stir bar. ^1H NMR spectra were recorded in CDCl_3 at 400 MHz and ^{13}C NMR spectra were recorded in CDCl_3 at 100 MHz respectively, ^1H and ^{13}C NMR were referenced to CDCl_3 at δ 7.260 and 77.0 respectively. GC-MS was obtained using electron ionization (Agilent Technologies 7890A/5975C). HRESIMS spectra were acquired using an Agilent 6210 ESI/TOF mass spectrometer. IR spectra were obtained as potassium bromide pellets or as liquid films between two potassium bromide pellets with a Bruker Vector 22 spectrometer. TLC was performed using commercially prepared 100-400 mesh silica gel plates (GF_{254}), and visualization was effected at 254 nm. All the other chemicals were purchased from Aldrich Chemicals. Commercial reagents were used without further purification.

II. General methods for the synthesis of 2-aminopyridine derivatives




A mixture of 2-fluoro-3-iodopyridine (1 mmol), acetamidine hydrochloride (1.2 mmol), NaOH (2.5 mmol), H_2O (5 equiv.) and DMSO (2.5 mL) was added successively in a 25 mL Schlenk tube. After stirring for 24 h at 130 $^\circ\text{C}$, the solution was filtered through a small amount of silica gel. Then the residue was concentrated in vacuo and the crude was purified by flash chromatography with n-hexane/ethyl acetate (2/1, v/v) to afford the 3-iodopyridin-2-amine as a pale-yellow solid in 95% yield.

III General methods for the Synthesis of *N,N*-dimethylpyridin-2-amines




A mixture of 2-fluoro-3-nitropyridine (1 mmol), acetamidine hydrochloride (1.2 mmol), NaOH (2.0 mmol) and DMF (3 mL) was added successively in a 25 mL Schlenk tube. After stirring for 24 h at 130 $^\circ\text{C}$, the solution was filtered through a small amount of silica gel. Then the residue was concentrated in vacuo and the crude was purified by flash chromatography with n-hexane/ethyl acetate (1/1, v/v) to afford the *N,N*-dimethyl-3-nitropyridin-2-amine as a pale-yellow solid in 93% yield.

IV. Characterization data for all prepared compounds




3-iodopyridin-2-amine^[1]

GC-MS (EI, 70 Ev) m/z. 220, 127, 93, 66. ¹H NMR (400 MHz, CDCl₃) δ 8.02 (dd, *J* = 4.8, 1.5 Hz, 1H), 7.86 (dd, *J* = 7.7, 1.6 Hz, 1H), 6.39 (dd, *J* = 7.7, 4.9 Hz, 1H), 5.00 (s, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 157.55, 147.80, 147.14, 115.33, 77.65.




6-iodopyridin-2-amine^[2]

GC-MS (EI, 70 Ev) m/z. 220, 127, 93, 66. ¹H NMR (600 MHz, CDCl₃) δ 7.10 – 6.92 (m, 2H), 6.41 (d, *J* = 7.6 Hz, 1H), 4.64 (s, 2H); ¹³C NMR (150 MHz, CDCl₃) δ 158.50, 138.93, 124.30, 115.68, 107.28.




6-bromopyridin-2-amine^[3]

GC-MS (EI, 70 Ev) m/z. 174, 172, 93, 63. ¹H NMR (600 MHz, CDCl₃) δ 7.21 (t, *J* = 7.8 Hz, 1H), 6.74 (d, *J* = 7.5 Hz, 1H), 6.37 (d, *J* = 8.1 Hz, 1H), 4.93 (s, 2H); ¹³C NMR (151 MHz, CDCl₃) δ 158.73, 139.76, 139.70, 116.57, 106.77.




3-bromopyridin-2-amine^[4]

GC-MS (EI, 70 Ev) m/z. 174, 172, 145, 93. ¹H NMR (600 MHz, CDCl₃) δ 7.99 (d, *J* = 4.8 Hz, 1H), 7.68 – 7.56 (m, 1H), 6.51 (dd, *J* = 7.7, 4.9 Hz, 1H), 5.11 (s, 2H); ¹³C NMR (150 MHz, CDCl₃) δ 155.60, 146.88, 140.26, 114.82, 104.38.




5-bromopyridin-2-amine^[5]

GC-MS (EI, 70 Ev) m/z.172, 145, 93, 66. ¹H NMR (600 MHz, Acetone) δ 7.85 (d, *J* = 2.4 Hz, 1H), 7.36 (dd, *J* = 8.8, 2.5 Hz, 1H), 6.40 (dd, *J* = 8.8, 0.5 Hz, 1H), 5.52 (s, 2H). ¹³C NMR (150 MHz, Acetone) δ 158.72, 148.30, 139.33, 109.90, 106.06.




6-chloropyridin-2-amine^[6]

GC-MS (EI, 70 Ev) m/z. 128, 101, 93, 66. ¹H NMR (600 MHz, Acetone) δ 7.38 (t, *J* = 7.8 Hz, 1H), 6.54 (d, *J* = 7.5 Hz, 1H), 6.48 (d, *J* = 8.1 Hz, 1H), 5.83 (s, 2H). ¹³C NMR (150 MHz, Acetone) δ 160.95, 149.83, 140.64, 111.92, 107.08.




5-chloropyridin-2-amine^[7]

GC-MS (EI, 70 Ev) m/z.128, 101, 93, 66. ¹H NMR (600 MHz, Acetone) δ 7.77 (d, *J* = 3 Hz, 1H), 7.25 (dd, *J* = 8.8, 2.7 Hz, 1H), 6.43 (dd, *J* = 8.8, 0.6 Hz, 1H), 5.49 (s, 2H). ¹³C NMR (150 MHz, Acetone) δ 158.53, 146.00, 136.75, 118.73, 109.20.




3-fluoropyridin-2-amine^[8]

GC-MS (EI, 70 Ev) m/z. 112, 85, 57. ¹H NMR (400 MHz, CDCl₃) δ 7.82 (d, *J* = 5.0 Hz, 1H), 7.17 (ddd, *J* = 10.9, 7.9, 1.3 Hz, 1H), 6.59 (ddd, *J* = 8.3, 5.0, 3.5 Hz, 1H), 4.78 (s, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 148.53 (d, *J*_{C-F} = 12.52 Hz, 1C), 146.91 (d, *J*_{C-F} = 252.5 Hz, 1C), 142.84 (d, *J*_{C-F} = 5.96 Hz, 1C), 121.39 (d, *J*_{C-F} = 15.35 Hz, 1C), 113.79 (d, *J*_{C-F} = 1.72 Hz, 1C).




3-fluoro-4-iodopyridin-2-amine^[9]

GC-MS (EI, 70 Ev) m/z. 238, 221, 84, 57. ¹H NMR (400 MHz, CDCl₃) δ 7.48 (d, *J* = 5.3 Hz, 1H), 6.98 (dd, *J* = 5.3, 3.9 Hz, 1H), 4.76 (s, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 148.16 (d, *J*_{C-F} = 37.57 Hz, 1C), 146.84 (d, *J*_{C-F} = 199.07 Hz, 1C), 143.44 (d, *J*_{C-F} = 6.97 Hz, 1C), 123.48 (d, *J*_{C-F} = 2.83 Hz, 1C), 90.49 (d, *J*_{C-F} = 20.2 Hz, 1C).




3-chloro-5-fluoropyridin-2-amine

GC-MS (EI, 70 Ev) m/z. 146, 119, 111, 84. ¹H NMR (400 MHz, CDCl₃) δ 7.89 (d, *J* = 2.6 Hz, 1H), 7.34 (dd, *J* = 7.5, 2.6 Hz, 1H), 4.81 (s, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 153.94 (s, 1C), 151.54 (d, *J*_{C-F} = 12.02 Hz, 1C), 133.16 (d, *J*_{C-F} = 24.04 Hz, 1C), 124.95 (d, *J*_{C-F} = 22.83 Hz, 1C), 144.35 (d, *J*_{C-F} = 4.9 Hz, 1C).




3,5-dibromopyridin-2-amine^[10]

GC-MS (EI, 70 Ev) m/z. 254, 252, 249, 170. ¹H NMR (600 MHz, Acetone) δ 8.03 (d, *J* = 2.4 Hz, 1H), 7.88 (d, *J* = 1.8 Hz, 1H), 5.96 (s, 2H). ¹³C NMR (150 MHz, Acetone) δ 156.33, 148.40, 142.31, 106.14, 104.48.




6-(trifluoromethyl)pyridin-2-amine^[11]

GC-MS (EI, 70 Ev) m/z. 162, 143, 135, 115, 93, 66. ¹H NMR (600 MHz, Acetone) δ 7.46 (t, *J* = 7.8 Hz, 1H), 6.80 (d, *J* = 7.2 Hz, 1H), 6.65 (d, *J* = 8.4 Hz, 1H), 5.84 (s, 2H). ¹³C NMR (150 MHz, Acetone) δ 160.049 (s, 1C), 145.82 (dd, *J*_{C-F} = 66.59, 66.44 Hz, 1C), 138.23 (s, 1C), 122.00 (d, *J*_{C-F} = 273.31 Hz, 1C), 111.756 (s, 1C), 108.38 (dd, *J*_{C-F} = 6.80, 6.80 Hz, 1C)




4-(trifluoromethyl)pyridin-2-amine^[12]

GC-MS (EI, 70 Ev) m/z.162, 143, 135, 116. ¹H NMR (600 MHz, Acetone) δ 8.17 (d, *J* = 4.8 Hz, 1H), 6.81 (s, 1H), 6.77 (d, *J* = 4.8 Hz, 1H), 5.94 (s, 2H). ¹³C NMR (150 MHz, Acetone) δ 161.31 (s, 1C), 150.68 (s, 1C), 139.56 (dd, *J*_{C-F} = 65.53, 65.69 Hz, 1C), 124.36 (dd, *J*_{C-F} = 544.36, 544.51 Hz, 1C), 108.03 (t, *J*_{C-F} = 3.322 Hz, 1C), 104.25 (t, *J*_{C-F} = 4.228 Hz, 1C).




3-chloro-5-(trifluoromethyl)pyridin-2-amine^[13]

GC-MS (EI, 70 Ev) m/z.196, 177, 169, 161, 141. ¹H NMR (151 MHz, Acetone) δ 16.99 (d, *J* = 1.8 Hz, 1H), 13.80 (d, *J* = 3.9 Hz, 1H), 3.66 (s, 2H). ¹³C NMR (150 MHz, Acetone) δ 158.18 (s, 1C), 144.10 (dd, *J*_{C-F} = 8.91, 8.76Hz, 1C), 133.41(dd, *J*_{C-F} = .80, 6.80 Hz, 1C), 124.07(dd, *J*_{C-F} = 540.28, 540.28 Hz, 1C), 115.59 (dd *J*_{C-F} = 66.44, 66.59 Hz, 1C), 113.48 (s, 1C).




3-nitropyridin-2-amine^[14]

GC-MS (EI, 70 Ev) m/z. 139, 122, 93, 66. ¹H NMR (600 MHz, Acetone) δ 8.51 – 8.23 (m, 2H), 7.46 (s, 2H), 6.80 (dd, *J* = 8.3, 4.5 Hz, 1H). ¹³C NMR (150 MHz, Acetone) δ 156.85, 154.91, 135.60, 128.56, 113.70.




5-nitropyridin-2-amine^[15]

GC-MS (EI,70 Ev) m/z.139, 109, 93, 66. ¹H NMR (600 MHz, Acetone) δ 8.91 (d, *J* = 2.8 Hz, 1H), 8.20 (dd, *J* = 9.2, 2.8 Hz, 1H), 6.89 (s, 2H), 6.73 – 6.63 (m, 1H). ¹³C NMR (150 MHz, Acetone) δ 163.81, 147.11, 136.11, 133.11, 107.47.




6-methyl-5-nitropyridin-2-amine^[16]

GC-MS(EI,70Ev) m/z 153, 136, 80. ¹H NMR (600 MHz, CDCl₃) δ 7.63 (d, *J* = 9.1 Hz, 1H), 6.90 (s, 2H), 5.92 (d, *J* = 9.1 Hz, 1H), 2.15 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 151.71, 146.56, 125.22, 124.74, 96.21, 15.49.




4-methyl-5-nitropyridin-2-amine^[16]

GC-MS(EI, 70Ev) m/z.153, 136, 80, 53. ¹H NMR (600 MHz, CD₃Cl+DMSO) δ 8.76 (s, 1H), 7.29 (s, 2H), 6.31 (s, 1H), 2.47 (s, 3H). ¹³C NMR (150 MHz, CD₃Cl+DMSO) δ 160.46, 146.47, 142.22, 133.57, 106.87, 19.15.




4-methylpyridin-2-amine^[17]

GC-MS (EI, 70 Ev) m/z. 108, 93, 51. ¹H NMR (600 MHz, CDCl₃) δ 7.91 (d, *J* = 5.4 Hz, 1H), 6.44 (d, *J* = 5.4 Hz, 1H), 6.28 (s, 1H), 4.69 (s, 2H), 2.18 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 158.61, 148.47, 147.37, 115.08, 108.71, 20.71.




3-methylpyridin-2-amine^[18]

GC-MS (EI, 70 Ev) m/z. 108, 93, 51. ¹H NMR (600 MHz, CDCl₃) δ 7.91 (dd, *J* = 5.0, 1.2 Hz, 1H), 7.22 (ddd, *J* = 7.2, 1.7, 0.8 Hz, 1H), 6.57 (dd, *J* = 7.2, 5.1 Hz, 1H), 4.47 (s, 2H), 2.08 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 157.07, 145.44, 137.61, 116.45, 114.23, 17.00.




5-chloro-4-fluoropyrimidin-2-amine

GC-MS (EI, 70 Ev) m/z. 147, 120, 114, 40; ESI-HRMS (m/z): [M+H]⁺, calculated for C₄H₄ClFN₃, 148.0072, found 148.0074; ¹H NMR (600 MHz, Acetone) δ 8.13 (s, 1H), 7.16 (d, *J* = 180.3 Hz, 2H). ¹³C NMR (150 MHz, Acetone) δ 163.47 (d, *J*_{C-F} = 18.57 Hz, 1C), 162.11 (d, *J*_{C-F} = 210.65 Hz, 1C), 156.47 (d, *J*_{C-F} = 57.08 Hz, 1C), 111.21 (d, *J*_{C-F} = 6.49 Hz, 1C).




pyrazin-2-amine^[19]

GC-MS (EI, 70 Ev) m/z. 95, 68, 41. ¹H NMR (600 MHz, Acetone) δ 7.98 (d, *J* = 1.2 Hz, 1H), 7.89 (dd, *J* = 2.4, 2.4 Hz, 1H), 7.73 (d, *J* = 2.7 Hz, 1H), 5.84 (s, 2H). ¹³C NMR (150 MHz, Acetone) δ 156.97, 142.74, 133.5, 133.4.



N,N-dimethyl-3-nitropyridin-2-amine^[20]


GC-MS (EI, 70 Ev) m/z. 167, 119, 93, 79, 66. ¹H NMR (600 MHz, Acetone) δ 8.35 (dd, *J* = 4.4, 1.6 Hz, 1H), 8.15 (dd, *J* = 8.0, 1.6 Hz, 1H), 6.78 (dd, *J* = 8.0, 4.5 Hz, 1H), 3.03 (s, 6H). ¹³C NMR (150 MHz, Acetone) δ 153.61, 152.31, 136.02, 132.79, 112.72, 40.11 (2C).



N-(3,5-dichloro-4,6-difluoropyridin-2-yl)acetamide

GC-MS (EI, 70 Ev) m/z. 239, 223, 204, 177. ESI-HRMS (m/z): [M+H]⁺, calculated for C₇H₆Cl₂F₂N₃, 239.9901, found 239.9906, ¹H NMR (600 MHz, Acetone) δ 6.72 (s, 1H), 6.27 (s, 1H), 2.06 (s, 3H). ¹³C NMR (150 MHz, Acetone) δ 161.20 (t, *J*_{C-F} = 3.93 Hz, 1C), 159.01

(s, 1C), 156.66 (d, J_{C-F} = 18.72 Hz, 1C), 155.08 (d, J_{C-F} = 18.72 Hz, 1C), 106.83 (dd, J_{C-F} = 25.07, 25.07 Hz, 2C), 20.78 (s, 1C).



N-(3,5,6-trifluoropyridin-2-yl)acetamide



GC-MS (EI, 70 Ev) m/z. 190, 148, 121. ESI-HRMS (m/z): $[M+H]^+$, calculated for $C_7H_6F_3N_2O$, 191.0413, found 191.0430; 1H NMR (600 MHz, Acetone) δ 9.36 (s, 1H), 7.97 (dd, J = 16.0, 8.4 Hz, 1H), 2.16 (s, 3H). ^{13}C NMR (150 MHz, Acetone) δ 168.8, 149.70 (d, J = 259.2 Hz, 1C), 145.83 (dd, J = 235.3, 16.4 Hz, 1C), 143.94 – 141.54 (m, 1C), 133.20 (t, J = 12.9 Hz, 1C), 121.51 – 117.37 (m, 1C), 23.1.



References:



1. M. S. Yusubov, R. Y. Yusubova, V. N. Nemykin, A. V. Maskaev, M. R. Geraskina, A. Kirsching and V. V. Zhdajin, *Eur. J. Org. Chem.*, **2012**, 30, 5935-5942.
2. C. Doebelin, P. Wagner, I. Bertion, F. Simonin, M. Schmitt, F. Bihei, J. J. Bourguignin, *RSC Adv.*, **2013**, 3, 10296-10300.
3. E. X. Zhang, D. X. Wang, Z. T. Huang, M. X. Wang, *J. Org. Chem.*, **2009**, 74, 8595–8603.
4. P. P. Jiang, X. J. Yang, *RSC Adv.*, **2016**, 6, 90031-90034.
5. Y. Zhou, H. Zhou, S. Liu, D. Oi, G. Shen, *Tetrahedron*, **2017**, 73, 3898-3904.
6. C. Ma, K. Hou, Z. Liu, Q. Yao, *Youji Huaxue*, **2014**, 34, 584-588.
7. Z. Gan, B. Hu, Q. Song, Y. Xu, *Synthesis* **2012**, 44, 1074-1078.
8. V. Garcia de Aranzazu, V. Martinez-Barrasa, C. Burgos, M. L. Izquierdo, J. Alvarez-Builla, *J. Org. Chem.*, **1999**, 64, 1007-1010.
9. S. Huang, X. Jin, Z. Liu, D. Poon, J. Tellew, Y. Wan, X. Wang, Y. Xie, PCT Int. Appl. **2011**, WO 2011025927 A1 Mar 03, **2011**.
10. Z. Zhou, Z. Ma, N. Behnke, H. Gao, L. Kurti, *J. Am. Chem. Soc.*, **2017**, 139, 115-118.
11. D. W. Hansen Jr., M. G. Currie, E. A. Hallinan, K. F. Fok, T. J. Hagen, A. A. Bergmanis, S. W. Kramer, L. F. Lee, S. Metz, U.S. **2000**, US 6046211 A Apr 04, **2000**.
12. T. Okada, PCT Int. Appl. 2011, WO 2011090122 A1 Jul 28, **2011**.
13. S. T. Andersen, PCT Int. Appl. 2014, WO 2014198278 A1 Dec 18, **2014**.
14. B. Maes, C. Wybon, C. Chen, C. B. Bheeter, Charles, S. Sergueev, PCT Int. Appl. **2017**, WO 2017046133 A1 Mar 23, **2017**.


15. X. Wang, A. Liu, X. Liu, L. He, X. Ou, M. Lei, L. Hu, G. Gao, Y. Yu, J. Zuo, *PCT Int. Appl.* **2014**, WO 2014187297 A1 Nov 27, **2014**.
16. P. Song, M. Chen, X. Ma, L. Xu, T. Liu, Y. Zhao, Y. Hu, *Bioorg. Med. Chem.*, **2015**, *23*, 1858-1868.
17. N. N. Smolyar, Y. M. Yutilov, *Russian J. Org. Chem.*, **2009**, *45*, 115-118.
18. J. Li, L. Liu, *RSC Advances*, **2012**, *2*, 10485-10487.
19. C. Lombardi, J. Day, N. Chandrasoma, D. Mitchell, M. Rodriguez, J. Farmer, M. G. Organ, Michael, *Organometallics*, **2017**, *362*, 251-254.
20. T. P. Petersen, A. F. Larsen, A. Ritzen, T. Ulven, *J. Org. Chem.*, **2013**, *78*, 4190-4195.

V. NMR Data
















7.856
7.852
7.369
7.365
7.354
7.350
6.411
6.410
6.396
6.395
5.520




158.723
148.301
139.334
109.899
106.058











7.776
7.771
7.263
7.259
7.249
7.244
6.440
6.439
6.426
6.425
5.488



205.322
158.528
146.000
136.750
118.727
109.201
29.378
29.249
29.121
28.993
28.865
28.736
28.608

